ScreenerHero

ARVNArvinas, Inc.

NAS · US · Healthcare · Biotechnology · arvinas.com
9.365USD-3.25%Mkt Cap: 612.34M $P/E: 36.02

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (P…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap612.34M $
Enterprise Value30.21M $
Revenue (TTM)316.70M $
Gross Profit307.70M $
Net Income (TTM)-80.80M $
Revenue/Share4.748 USD
Last Price9.365 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees246
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)36.02
P/E (Forward)-2.90
PEG—
EV/EBITDA-3.05
EV/Revenue0.10
P/S1.84
P/B1.05
EPS (TTM)0.24
EPS (Forward)-3.12
52W Range
6.96032% of range14.51
52W High14.51 USD
52W Low6.960 USD
Profitability
Gross Margin97.16%
Oper. Margin66.36%
EBITDA Margin-3.13%
Profit Margin-30.77%
ROE-18.63%
ROA-11.26%
Growth
Revenue Growth1014.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-273.80M $
CapEx (TTM)1.90M $
FCF Margin-29.84%
FCF Yield-15.43%
Net Debt-559.90M $
Net Debt/EBITDA56.56
Balance Sheet
Debt/Equity0.02
Current Ratio7.91
Quick Ratio7.54
Book Value/Sh8.609 USD
Cash/Share8.685 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.4 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.93 USD
Upside (mean)+48.7%
Target Range6.000 USD – 21.00 USD
$6.000+48.7% to mean$21.00
# Analysts14
Ownership
Shares Out.65.39M
Float56.81M
Insiders7.80%
Institutions84.21%
Short Interest
Short Ratio6.7d
Short % Float7.12%
Short % Out.6.11%
Shares Short4.00M
Short (prev mo.)4.27M
Technical
SMA 508.294 (+12.9%)
SMA 20010.60 (-11.6%)
Beta1.74
S&P 52W Chg18.16%
Avg Vol (30d)779.63K
Avg Vol (10d)662.09K
Technical Indicators
RSI (14)62.4
MACD0.2921
MACD Signal0.1996
MACD Hist.+0.0925
BB Upper9.646 USD
BB Middle8.654 USD
BB Lower7.662 USD
BB Width22.93%
ATR (14)0.4112 USD
Vol Ratio (20d)1.07x